{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:41:44Z","timestamp":1777614104428,"version":"3.51.4"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p>Ovarian cancer is one of the most lethal malignancies. The population at the risk is continually on the rise due to the acquired drug resistance, high relapse rate, incomplete knowledge of the etiology, cross-talk with other gynecological malignancies, and diagnosis at an advanced stage. Most ovarian tumors are thought to arise in surface epithelium somehow in response to changes in the hormonal environment. Prolonged treatment with hormone replacement therapy (HRT) is also considered a contributing factor. Estrogens influence the etiology and progression of the endocrine\/hormone-responsive cancers in a patient-specific manner. The concept of hormonal manipulations got attention during the last half of the 20th century when tamoxifen was approved by the FDA as the first selective estrogen receptor modulator (SERM). Endocrine therapy that has been found to be effective against breast cancer can be an option for ovarian cancer. It is now established that global changes in the epigenetic landscape are not only the hallmark of tumor development but also contribute to the development of resistance to hormone therapy. A set of functionally related genes involved in epigenetic reprogramming are controlled by specific transcription factors (TFs). Thus, the activities of TFs mediate important mechanisms through which epigenetic enzymes and co-factors modify chromatin for the worst outcome in a site-specific manner. Furthermore, the role of epigenetic aberrations involving histone modifications is established in ovarian cancer pathogenesis. This review aims to provide insights on the role of key epigenetic determinants of response as well as resistance to the hormone therapy, the current status of research along with its limitations, and future prospects of epigenetic agents as biomarkers in early diagnosis, prognosis, and personalized treatment strategies. Finally, the possibility of small phytoestrogenic molecules in combination with immunotherapy and epi-drugs targeting ovarian cancer has been discussed.<\/jats:p>","DOI":"10.3389\/fgene.2022.812077","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T09:00:11Z","timestamp":1657270811000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Insights Into the Role of Epigenetic Factors Determining the Estrogen Response in Estrogen-Positive Ovarian Cancer and Prospects of Combining Epi-Drugs With Endocrine Therapy"],"prefix":"10.3389","volume":"13","author":[{"given":"Sadia","family":"Sarwar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abir","family":"Alamro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fazlul","family":"Huq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amani","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1158\/0008-5472.can-06-2909","article-title":"Protein-coupled Receptor 30 (GPR30) Mediates Gene Expression Changes and Growth Response to 17beta-Estradiol and Selective GPR30 Ligand G-1 in Ovarian Cancer Cells","volume":"67","author":"Albanito","year":"2007","journal-title":"Cancer Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.3390\/cancers12061470","article-title":"An Overview of Candidate Therapeutic Target Genes in Ovarian Cancer","volume":"12","author":"Alexandrova","year":"2020","journal-title":"Cancers"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1016\/s0140-6736(07)60534-0","article-title":"Ovarian Cancer and Hormone Replacement Therapy in the Million Women Study","volume":"369","author":"Beral","year":"2007","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41576-018-0074-2","article-title":"Clinical Epigenetics: Seizing Opportunities for Translation","volume":"20","author":"Berdasco","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"B5","first-page":"2233","article-title":"CA125 Response Is Associated with Estrogen Receptor Expression in a Phase II Trial of Letrozole in Ovarian Cancer","volume":"8","author":"Bowman","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"9042","DOI":"10.1073\/pnas.160016897","article-title":"Down-regulation of p21WAF1\/CIP1 or p27Kip1 Abrogates Antiestrogen- Mediated Cell Cycle Arrest in Human Breast Cancer Cells","volume":"97","author":"Cariou","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0303-7207(94)90140-6","article-title":"Transcriptional Activation of C-Myc Proto-Oncogene by Estrogen in Human Ovarian Cancer Cells","volume":"11","author":"Chien","year":"1999","journal-title":"Mol. Cell Endocrinol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0303-7207(94)90140-6","article-title":"Transcriptional Activation of C-Myc Proto- Oncogene by Estrogen in Human Ovarian Cancer Cells","volume":"99","author":"Chien","year":"1994","journal-title":"Mol. Cell Endocrinol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s1040-8428(96)00216-8","article-title":"Estrogen Action in Human Ovarian Cancer","volume":"25","author":"Clinton","year":"1997","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ygyno.2021.07.016","article-title":"Tolerability of Maintenance Olaparib in Newly Diagnosed Patients with Advanced Ovarian Cancer and a BRCA Mutation in the Randomized Phase III SOLO1 Trial","volume":"163","author":"Colombo","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1158\/2159-8290.CD-19-1493","article-title":"Epigenetic Switch\u2013Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer","volume":"10","author":"Daly","year":"2020","journal-title":"Cancer Discov."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1158\/2159-8290.CD-19-1493","article-title":"Epigenetic Switch-Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer","volume":"10","author":"Deblois","year":"2020","journal-title":"Cancer Discov."},{"key":"B12","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ygyno.2003.08.021","article-title":"PhaseII Trial of Anastrazole in Women with Asymptomatic Mullerian Cancer","volume":"91","author":"DelCarmen","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ygyno.2012.02.019","article-title":"A Phase II Evaluation of Belinostat and Carboplatin in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma: a Gynecologic Oncology Group Study","volume":"125","author":"Dizon","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1128\/mcb.19.8.5363","article-title":"Purification and Identification of P68 RNA Helicase Acting as a Transcriptional Co-activator Specific for the Activation Function 1 of Human Estrogen Receptor Alpha","volume":"19","author":"Endoh","year":"1999","journal-title":"Mol. Cell Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/(sici)1097-0215(20000101)85:1<98::aid-ijc18>3.0.co;2-a","article-title":"Activity of Cisplatin and ICI 182,780 on Estrogen Receptor Negative Ovarian Cancer Cells: Cell Cycle and Cell Replication Rate Perturbation, Chromatin Texture Alteration and Apoptosis Induction","volume":"85","author":"Ercoli","year":"2000","journal-title":"Inter J. Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s10552-013-0174-4","article-title":"Australian cancer study (Ovarian Cancer); Australian ovarian cancer study group; et al. Cigarette smoking and risk of ovarian cancer: A pooled analysis of 21 case-control studies","volume":"24","author":"Faber","year":"2013","journal-title":"Cancer Causes Control"},{"key":"B17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/s0140-6736(71)92335-x","article-title":"Incessant Ovulation-A Factor in Ovarian Neoplasia?","volume":"2","author":"Falhalla","year":"1971","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.steroids.2007.12.025","article-title":"Association of the Membrane Estrogen Receptor, GPR30, with Breast Tumor Metastasis and Transactivation of the Epidermal Growth Factor Receptor","volume":"73","author":"Filardo","year":"2008","journal-title":"Steroids"},{"key":"B19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10549-006-9208-x","article-title":"Pre-menopausal Breast Cancer and Aromatase Inhibitors: Treating a New Generation of Women","volume":"99","author":"Freedman","year":"2006","journal-title":"Breast Cancer Res. Treat."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1038\/s41467-021-22024-3","article-title":"Epigenetic Mechanisms in Breast Cancer Therapy and Resistance","volume":"12","author":"Garcia-Martinez","year":"2021","journal-title":"Nat. Commun."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1001\/archinte.164.20.2253","article-title":"Hormone Therapy and the Impact of Estrogen Intake on the Impact of Ovarian Cancer","volume":"20","author":"Glud","year":"2004","journal-title":"Arch. Intern Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1210\/me.2002-0438","article-title":"Stromal Cell-Derived Factor 1, a Novel Target of Estrogen Receptor Action, Mediates the Mitogenic Effects of Estradiol in Ovarian and Breast Cancer Cells","volume":"17","author":"Hall","year":"2003","journal-title":"Mol. Endocrinol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s12253-010-9340-0","article-title":"Estrogen Receptor Alpha Expression in Ovarian Cancer Predicts Longer Overall Survival","volume":"17","author":"Halon","year":"2011","journal-title":"Pathol. Oncol. Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2016.09.023","article-title":"Epigenetic Regulation of Active Chinese Herbal Components for Cancer Prevention and Treatment: A Follow-Up Review","volume":"114","author":"Huang","year":"2016","journal-title":"Pharmacol. Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"37663","DOI":"10.18632\/oncotarget.5438","article-title":"Molecular Profiling of Low Grade Serous Ovarian Tumours Identifies Novel Candidate Driver Genes","volume":"6","author":"Hunter","year":"2015","journal-title":"Oncotarget"},{"key":"B26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1757-2215-6-510.1186\/1757-2215-6-51","article-title":"GPER-1 Acts as a Tumor Suppressor in Ovarian Cancer","volume":"6","author":"Ignatov","year":"2013","journal-title":"J. Ovarian Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/jnci\/93.19.1449","article-title":"Selective Estrogen Receptor Modulation and Reduction in Risk of Breast Cancer, Osteoporosis, and Coronary Heart Disease","volume":"93","author":"Jordan","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"key":"B28","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/s0960-9776(11)70287-9","article-title":"The St. Gallen Prize Lecture 2011: Evolution of Long-Term Adjuvant Anti Hormone Therapy: Consequences and Opportunities","volume":"20","author":"Jordan","year":"2011","journal-title":"Breast"},{"key":"B29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/bcr78","article-title":"Estrogen Receptors: Selective Ligands, Partners, and Distinctive Pharmacology","volume":"55","author":"Katzenellenbogan","year":"2000","journal-title":"Rec. Prog. Horm. Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"5582","DOI":"10.1200\/jco.2007.25.18_suppl.5582","article-title":"Antitumor Activity of Letrozole in Patients with Recurrent Advanced Low Malignant Potential or Low Grade Serous Ovarian Tumors","volume":"25","author":"Kavanagh","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.canlet.2006.01.017","article-title":"The Role of Tamoxifen in Combination with Cisplatin on Oral Squamous Cell Carcinoma Cell Lines","volume":"245","author":"Kim","year":"2005","journal-title":"Can. Lets"},{"key":"B32","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1210\/endo.138.3.4979","article-title":"Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors Alpha and Beta","volume":"138","author":"Kuiper","year":"1997","journal-title":"Endocrinology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.1210\/endo.139.10.6216","article-title":"Interaction of Estrogenic Chemicals and Phytoestrogens with Estrogen Receptor Beta","volume":"139","author":"Kuiper","year":"1998","journal-title":"Endocrinology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.3390\/cancers12061647","article-title":"Estrogen Signaling and its Potential as a Target for Therapy in Ovarian Cancer","volume":"12","author":"Langdon","year":"2020","journal-title":"Cancers"},{"key":"B35","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0960-0760(94)90019-1","article-title":"The Regulation of Growth and Protein Expression by Estrogen In Vitro: a Study of Human Ovarian Carcinoma Cell Lines","volume":"5","author":"Langdon","year":"1994","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1038\/s41467-018-03590-5","article-title":"C\/EBPbeta Enhances Platinum Resistance of Ovarian Cancer Cells by Reprogramming H3K79 Methylation","volume":"9","author":"Liu","year":"2018","journal-title":"Nat. Commun."},{"key":"B37","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s11912-015-0464-y","article-title":"Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?","volume":"17","author":"Lue","year":"2015","journal-title":"Curr. Oncol. Rep."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1210\/en.2003-0709","article-title":"Tamoxifen Inhibits Cell Proliferation via Mitogen-Activated Protein Kinase Cascades in Human Ovarian Cancer Cell Lines in a Manner Not Dependent on the Expression of Estrogen Receptor or the Sensitivity to Cisplatin","volume":"145","author":"Mabuchi","year":"2004","journal-title":"Endocrinology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"25946","DOI":"10.18632\/oncotarget.25408","article-title":"Low Expression of G Protein-Coupled Oestrogen Receptor 1 (GPER) Is Associated with Adverse Survival of Breast Cancer Patients","volume":"9","author":"Martin","year":"2018","journal-title":"Oncotarget"},{"key":"B40","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ygyno.2014.03.563","article-title":"Estrogen Receptor Expression and Increased Risk of Lymphovascular Space Invasion in High-Grade Serous Ovarian Carcinoma","volume":"133","author":"Matsuo","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/bjc.1994.326","article-title":"Tamoxifen Delays the Development of Resistance to Cisplatin in Human Melanoma and Ovarian Cancer Cell Lines","volume":"70","author":"McClay","year":"1994","journal-title":"Brit J. Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","article-title":"Roles of the Raf\/MEK\/ERK Pathway in Cell Growth, Malignant Transformation and Drug Resistance","volume":"1773","author":"McCubrey","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"B43","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.cell.2007.05.003","article-title":"PCNA, the Maestro of the Replication Fork","volume":"129","author":"Moldovan","year":"2007","journal-title":"Cell"},{"key":"B44","doi-asserted-by":"publisher","first-page":"6947","DOI":"10.1073\/pnas.96.12.6947","article-title":"An Estrogen Receptor-Selective Co-regulator that Potentiates the Effectiveness of Antiestrogens and Represses the Activity of Estrogens","volume":"12","author":"Montano","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e113354","DOI":"10.1371\/journal.pone.0113354","article-title":"Estrogen Induces Global Reorganization of Chromatin Structure in Human Breast Cancer Cells","volume":"9","author":"Mourad","year":"2014","journal-title":"PLoS ONE"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1210\/endo-121-5-1759","article-title":"Characterization of the Estrogen-Induced pS2 Protein Secreted by the Human Breast Cancer Cell Line MCF-7","volume":"121","author":"Munez","year":"1987","journal-title":"Endocrinology"},{"key":"B47","first-page":"53","article-title":"Combinations of Resveratrol, Cisplatin and Oxaliplatin Applied to Human Ovarian Cancer Cells","volume":"32","author":"Nessa","year":"2012","journal-title":"Anti Res."},{"key":"B48","first-page":"3789","article-title":"Synergism from Combinations of Cisplatin and Oxaliplatin with Quercetin and Thymoquinone in Human Ovarian Tumor Models","volume":"31","author":"Nessa","year":"2011","journal-title":"Anti Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1677\/erc.1.01039","article-title":"Estrogen Receptor Alpha Mediates Gene Expression Changes and Growth Response in Ovarian Cancer Cells Exposed to Estrogen","volume":"12","author":"O\u2019Donnell","year":"2005","journal-title":"Endocr. Relat. Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/s0140-6736(15)00138-5","article-title":"Hormone Therapy and Ovarian Cancer","volume":"386","author":"Onwude","year":"2015","journal-title":"Lancet"},{"key":"B51","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1046\/j.1525-1438.2001.01059.x","article-title":"A Combination of Platinum and Tamoxifen in Advanced Ovarian Cancer Failing Platinum Based Chemotherapy: Results of a Phase II Study","volume":"11","author":"Panici","year":"2001","journal-title":"Int. J. Gyn Can."},{"key":"B52","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1159\/000077436","article-title":"Hormonal Therapy with Letrozole for Relapsed Epithelial Epithelial Ovarian Cancer. Long Term Results of a Phase II Study","volume":"66","author":"Papadimititrou","year":"2004","journal-title":"Oncology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.critrevonc.2003.09.003","article-title":"The Biological Role of Estrogen Receptors \u03b1 and \u03b2 in Cancer","volume":"50","author":"Pearce","year":"2004","journal-title":"Crit. Rev. Oncology\/Hematology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ygyno.2018.08.016","article-title":"Histotype Classification of Ovarian Carcinoma: A Comparison of Approaches","volume":"151","author":"Peres","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.1093\/emboj\/18.17.4608","article-title":"Structure of the Ligand Binding Domain of Oestrogen Receptor Beta in the Presence of a Partial Agonist and a Full Antagonist","volume":"18","author":"Pike","year":"1999","journal-title":"EMBO J."},{"key":"B56","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/jnci\/94.7.497","article-title":"Hormone Replacement Therapy and the Risk of Invasive Epithelial Ovarian Cancer in Swedish Women","volume":"94","author":"Riman","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"B57","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1677\/erc.0.0100261","article-title":"How to Target Estrogen Receptor-Negative Breast Cancer? Endocrine-Related Cancer","volume":"10","author":"Rochefort","year":"2003","journal-title":"Endocr. Relat. Cancer Endocr. Relat. Cancer"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.285.11.1460","article-title":"Estrogen Replacement Therapy and Ovarian Cancer Mortality in a Large Prospective Study of US Women","volume":"285","author":"Rodriguez","year":"2001","journal-title":"JAMA"},{"key":"B59","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3389\/fphys.2018.00907","article-title":"Tamoxifen-induced Apoptosis of MCF-7 Cells via GPR30\/PI3K\/MAPKs Interactions: Verification by ODE Modeling and RNA Sequencing","volume":"9","author":"Rouhimoghadam","year":"2018","journal-title":"Front. Physiol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.3390\/cancers11111720","article-title":"The Histone Methyltransferase DOT1L Is a Functional Component of Estrogen Receptor Alpha Signaling in Ovarian Cancer Cells","volume":"11","author":"Salvati","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.2147\/dddt.s288707","article-title":"Enhanced Accumulation of Cisplatin in Ovarian Cancer Cells from Combination with Wedelolactone and Resulting Inhibition of Multiple Epigenetic Drivers","volume":"15","author":"Sarwar","year":"2021","journal-title":"Drug Des. Devel Ther."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/0959-8049(92)90029-2","article-title":"Synergistic Antiproliferative Activity of Tamoxifen and Cisplatin on Primary Ovarian Tumours","volume":"28","author":"Scambia","year":"1992","journal-title":"Eur. J. Cancer"},{"key":"B64","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/s1470-2045(13)70253-5","article-title":"Hormone-receptor Expression and Ovarian Cancer Survival: an Ovarian Tumor Tissue Analysis Consortium Study","volume":"14","author":"Sieh","year":"2013","journal-title":"Lancet Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.steroids.2013.01.008","article-title":"New Insights on the Role of Hormonal Therapy in Ovarian Cancer","volume":"78","author":"Simpkins","year":"2013","journal-title":"Steroids"},{"key":"B66","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/j.1525-1438.2007.01069.x","article-title":"Tamoxifen Is Safe and Effective in Gynecological Cancer Patients with Renal Dysfunction","volume":"18","author":"Sirisabya","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.ygyno.2019.12.033","article-title":"Low-grade Serous Ovarian Cancer: State of the Science","volume":"156","author":"Slomovitz","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ygyno.2006.12.030","article-title":"An Inhibitory Effect on Cell Proliferation by Blockage of the MAPK\/estrogen receptor\/MDM2 Signal Pathway in Gynecologic Cancer","volume":"105","author":"Suga","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1158\/1078-0432.ccr-06-2245","article-title":"Insulin-like Growth Factor Binding Proteins IGFBP3, IGFBP4, and IGFBP5 Predict Endocrine Responsiveness in Patients with Ovarian Cancer","volume":"13","author":"Walker","year":"","journal-title":"Clin. Cancer Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.ygyno.2007.05.009","article-title":"Estrogen-regulated Gene Expression Predicts Response to Endocrine Therapy in Patients with Ovarian Cancer","volume":"106","author":"Walker","year":"","journal-title":"Gynecol. Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12943-018-0855-4","article-title":"Epigenetics in Ovarian Cancer: Premise, Properties, and Perspectives","volume":"17","author":"Yang","year":"2018","journal-title":"Mol. Cancer"},{"key":"B72","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ymeth.2019.04.015","article-title":"Genome-wide CRISPR-Cas9 Screening in Mammalian Cells","author":"Yu","year":"2019","journal-title":"Methods"},{"key":"B73","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1038\/onc.2011.611","article-title":"Candidate DNA Methylation Drivers of Acquired Cisplatin Resistance in Ovarian Cancer Identified by Methylome and Expression Profiling","volume":"31","author":"Zeller","year":"2012","journal-title":"Oncogene"},{"key":"B74","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13045-017-0400-8","article-title":"Prognostic and Therapeutic Value of Disruptor of Telomeric Silencing-1-like (DOT1L) Expression in Patients with Ovarian Cancer","volume":"10","author":"Zhang","year":"2017","journal-title":"J. Hematol. Oncol."}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2022.812077\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T09:00:30Z","timestamp":1657270830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2022.812077\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,8]]},"references-count":75,"alternative-id":["10.3389\/fgene.2022.812077"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2022.812077","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,8]]},"article-number":"812077"}}